TITLE

Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study

AUTHOR(S)
Ravoet, Christophe; Mineur, Philippe; Robin, Valérie; Debusscher, Louisette; Bosly, André; André, Marc; Housni, Hakim; Soree, Anne; Bron, Dominique; Martiat, Philippe; Robin, Valérie; Bosly, André; André, Marc; El Housni, Hakim
PUB. DATE
November 2008
SOURCE
Annals of Hematology;Nov2008, Vol. 87 Issue 11, p881
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Although an activating mutation of Ras is commonly observed in myelodysplastic syndrome (MDS), the role of Ras in the natural history of MDS remains largely unknown. We prospectively studied efficiency and tolerance of lonafarnib, a compound able to inhibit Ras signalling pathway through an inhibition of farnesyl transferase, in patients with MDS or secondary acute myeloid leukaemia (sAML). Lonafarnib was administered orally at a dose of 200 mg twice daily for three courses of 4 weeks (separated by 1 to 4 weeks without treatment). Sixteen patients were included: FAB/RAEB ( n = 10), RAEB-T ( n = 2), sAML ( n = 2) and chronic myelomonocytic leukaemia (CMML; n = 2); WHO/RAEB-1 ( n = 4), RAEB-2 ( n = 5), AML ( n = 5), CMML ( n = 2). Median age was 70 (53–77) years. The karyotype was complex or intermediate in 11 patients, and the International Prognostic Scoring Systems (IPSS) risk groups were low in two patients, INT-1 in one patient, INT-2 in four patients and high in six patients (unknown or not applicable in three patients). Among the 14 patients tested, five had Ras mutations in codons 12, 13 or 61 of N-Ras, K-Ras or H-Ras. One patient was excluded of the analysis for protocol violation, and 15 patients were assessable for tolerance. Gastrointestinal toxicities (diarrhoea, nausea and anorexia) and myelosuppression were the major side effects. Other toxicities included infections, fatigue, increase of liver enzymes, arrhythmia and skin rash. One patient died of infection, and the treatment was stopped in one other who developed atrial fibrillation. Doses were reduced in all but one patient treated with more than one course of farnesyl transferase inhibitor. Responses were assessable in 12 patients. A partial response in one sAML patient and a very transient decrease of blast cell count with normalisation of karyotype in one MDS patient were observed. No relation between improvement of marrow parameters and detected Ras mutations was observed. Lonafarnib alone, administered following our schedule, has shown limited activity in patients with MDS or secondary AML. Gastrointestinal and haematological toxicities appear the limiting toxicity in this population of patients.
ACCESSION #
34509823

 

Related Articles

  • On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Feldman, E. J.; Cortes, J.; DeAngelo, D. J.; Holyoake, T.; Simonsson, B.; O'Brien, S. G.; Reiffers, J.; Turner, A. R.; Roboz, G. J.; Lipton, J. H.; Maloisel, F.; Colombat, P.; Martinelli, G.; Nielsen, J. L.; Petersdorf, S.; Guilhot, F.; Barker, J.; Kirschmeier, P.; Frank, E.; Statkevich, P. // Leukemia (08876924);Sep2008, Vol. 22 Issue 9, p1707 

    Lonafarnib is an orally bio-available farnesyltransferase inhibitor that prevents farnesylation of specific target proteins including Ras. In a multicenter study, 67 patients with advanced myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) were treated with a continuous...

  • Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Giagounidis, A. A. N.; Germing, U.; Strupp, C.; Hildebrandt, B.; Heinsch, M.; Aul, C. // Annals of Hematology;Sep2005, Vol. 84 Issue 9, p569 

    The survival of patients with myelodysplastic syndromes is strongly affected by chromosomal abnormalities. Patients with an isolated del(5q31) have a favourable prognosis that worsens with the addition of another chromosomal abnormality. It has been reported that both patients with isolated...

  • Myelodysplastic Syndromes: Evolving Insights. Vercauteren, Suzanne M.; Karsan, Aly // Canadian Journal of Pathology;2011, Vol. 3 Issue 4, p31 

    The classification, pathogenesis, and diagnosis and of the entities that comprise myelodysplastic syndromes are reviewed. Factors governing prognosis are discussed, as are newer therapeutic modalities.

  • Prognostic Factors in Myelodysplastic Syndromes. TRIANTAFYLLIDIS, Irina; CIOBANU, Anca; STANCA, Oana; LUPU, Anca Roxana // Romanian Journal of Medical Practice;2012, Vol. 7 Issue 4, p295 

    Background: Myelodysplastic syndromes (MDS) are clonal disorders of hematopoietic stem cell and are characterized by ineffective hematopoiesis with normo- or hyper cellular bone marrow and cytopenia(s).The natural evolution of the disease consists of bone marrow failure (leading to infectious...

  • Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution. Bernasconi, P.; Klersy, C.; Boni, M.; Cavigliano, P. M.; Calatroni, S.; Giardini, I.; Rocca, B.; Zappatore, R.; Caresana, M.; Quarna, J.; Lazzarino, M.; Bernasconi, C. // Leukemia (08876924);Aug2005, Vol. 19 Issue 8, p1424 

    The impact of clinical parameters, International Prognostic Scoring System (IPSS) scores/cytogenetic categories, and some single cytogenetic defects on overall survival (OS) and time to myelodysplastic syndromes (MDS)/AML progression (progression-free interval (PFI)) was evaluated in 331 MDS...

  • ASSESSMENT OF PROGNOSTIC FACTORS IN MYELODYSPLASTIC SYNDROMES. Daniela, Georgescu; Oana, Patrinoiu; Mihaela, Popescu; Natalia, Ciuhu Anda // Therapeutics, Pharmacology & Clinical Toxicology;Jun2014, Vol. 18 Issue 2, p72 

    Myelodysplastic syndromes (MDSs) represent a heterogeneous group of bone marrow conditions characterized by peripheral blood cytopenias and increased risk for evolution to acute leukemia. An accurate risk group classification constitutes the start point for the establishment of the therapeutic...

  • Predicting the presence or absence of ringed sideroblasts in patients suspected of having a myelodysplastic syndrome and increased iron stores: a simple observation. Dorion, R P; Alomari, M; Wood, G C // Leukemia (08876924);Nov2001, Vol. 15 Issue 11, p1793 

    Presents a letter to the editor on myelodysplastic syndrome, published in the November 1, 2001 issue of the journal 'Leukemia'. Bone marrow examination of patients; Presence of ringed sideroblasts in patients.

  • Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan. Sasaki, H; Manabe, A; Kojima, S; Tsuchida, M; Hayashi, Y; Ikuta, K; Okamura, J; Koike, K; Ohara, A; Ishii, E; Komada, Y; Hibi, S; Nakahata, T // Leukemia (08876924);Nov2001, Vol. 15 Issue 11, p1713 

    We report a retrospective analysis of children with myelodys-plastic syndrome (MDS) diagnosed between 1990 and 1997 in Japan. In total, 189 patients were enrolled: 122 cases of primary MDS (26 RA, 18 RAEB, 25 RAEBt, 53 CMML/JMML), 24 cases with constitutional predisposition to MDS, and 43 cases...

  • myelodysplastic syndrome.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1523 

    A reference entry for "myelodysplastic syndrome" is presented.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics